Schrodinger Inc (SDGR)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $2.22B
Last updated: Nov 17, 2026 at 11:06 AM ET
Schrodinger Inc (SDGR) Earnings: Report Dates and Results
Schrodinger (SDGR) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Schrodinger reported EPS of -$0.50, above the -$0.66 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SDGR has an expected report date of Feb 23, 2027.
SDGR Earnings Call
The latest SDGR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 28 quarters below that had an estimate, SDGR beat 12 and missed 16. Revenue for the quarter ended Sep 30, 2026 was $64.49M, up 18.7% from $54.32M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.50 | -$0.66 | -$0.81 - -$0.53 | +24.24% | Beat | N/A | 7 | 2 up, 3 down | Nov 4, 2026 | $64.49M |
| Jun 30, 2026 | $0.08 | -$0.60 | N/A | +113.33% | Beat | N/A | 1 | 0 up, 0 down | Aug 5, 2026 | $58.89M |
| Mar 31, 2026 | -$0.62 | -$0.57 | -$0.59 - -$0.55 | -8.77% | Miss | N/A | 2 | 0 up, 0 down | May 5, 2026 | $58.59M |
| Dec 31, 2025 | -$0.18 | -$0.20 | N/A | +7.59% | Beat | N/A | 1 | 0 up, 0 down | Feb 25, 2026 | $87.23M |
| Sep 30, 2025 | -$0.45 | -$0.75 | -$0.92 - -$0.52 | +40.00% | Beat | N/A | 9 | 0 up, 1 down | Nov 5, 2025 | $54.32M |
| Jun 30, 2025 | -$0.65 | -$0.64 | -$0.64 - -$0.64 | -1.56% | Miss | N/A | 1 | 1 up, 0 down | Aug 6, 2025 | $54.76M |
| Mar 31, 2025 | -$0.64 | -$0.81 | -$0.81 - -$0.81 | +20.99% | Beat | N/A | 1 | 0 up, 0 down | May 7, 2025 | $59.55M |
| Dec 31, 2024 | -$0.24 | -$0.38 | -$0.38 - -$0.38 | +36.84% | Beat | N/A | 2 | 0 up, 1 down | Feb 26, 2025 | $88.32M |
| Sep 30, 2024 | -$0.87 | -$0.63 | -$0.85 - -$0.06 | -38.10% | Miss | N/A | 11 | 1 up, 0 down | Nov 12, 2024 | $35.29M |
| Jun 30, 2024 | -$0.74 | -$0.89 | -$0.98 - -$0.71 | +16.85% | Beat | N/A | 9 | 0 up, 0 down | Jul 31, 2024 | $47.33M |
| Mar 31, 2024 | -$0.76 | -$0.74 | -$0.86 - -$0.64 | -2.70% | Miss | N/A | 8 | 0 up, 1 down | May 1, 2024 | $36.60M |
| Dec 31, 2023 | -$0.41 | -$0.38 | -$0.53 - -$0.20 | -7.89% | Miss | N/A | 7 | 0 up, 0 down | Feb 28, 2024 | $74.13M |
| Sep 30, 2023 | -$0.70 | -$0.69 | -$0.91 - -$0.46 | -1.45% | Miss | N/A | 7 | 0 up, 0 down | Nov 1, 2023 | $42.57M |
| Jun 30, 2023 | -$0.60 | -$0.38 | -$0.56 - -$0.09 | -57.89% | Miss | N/A | 7 | 1 up, 1 down | Aug 2, 2023 | $35.19M |
| Mar 31, 2023 | -$0.23 | -$0.19 | N/A | -21.05% | Miss | N/A | 5 | 1 up, 0 down | May 4, 2023 | $64.78M |
| Dec 31, 2022 | -$0.38 | -$0.53 | -$0.65 - -$0.30 | +28.30% | Beat | N/A | 7 | 0 up, 0 down | Feb 28, 2023 | $56.84M |
| Sep 30, 2022 | -$0.50 | -$0.59 | -$0.82 - -$0.52 | +15.25% | Beat | N/A | 7 | 1 up, 0 down | Nov 3, 2022 | $36.98M |
| Jun 30, 2022 | -$0.17 | -$0.49 | N/A | +65.31% | Beat | N/A | N/A | 0 up, 0 down | Aug 4, 2022 | $38.47M |
| Mar 31, 2022 | -$0.27 | -$0.43 | -$0.60 - -$0.37 | +37.21% | Beat | N/A | 6 | 0 up, 0 down | May 4, 2022 | $48.66M |
| Dec 31, 2021 | -$0.43 | -$0.39 | -$0.59 - -$0.01 | -10.26% | Miss | N/A | 5 | 0 up, 0 down | Feb 24, 2022 | $46.17M |
| Sep 30, 2021 | -$0.38 | -$0.29 | N/A | -31.03% | Miss | N/A | 4 | 0 up, 0 down | Nov 10, 2021 | $29.85M |
| Jun 30, 2021 | -$0.32 | -$0.09 | N/A | -255.56% | Miss | N/A | 4 | N/A | Aug 12, 2021 | $29.78M |
| Mar 31, 2021 | -$0.27 | -$0.25 | -$0.29 - $0.00 | -8.00% | Miss | N/A | 4 | N/A | May 11, 2021 | $32.13M |
| Dec 31, 2020 | -$0.18 | -$0.08 | -$0.15 - $0.11 | -125.00% | Miss | N/A | 4 | N/A | Mar 4, 2021 | $33.03M |
| Sep 30, 2020 | -$0.22 | -$0.09 | -$0.28 - $0.04 | -144.44% | Miss | N/A | 4 | N/A | Nov 12, 2020 | $25.80M |
| Jun 30, 2020 | -$0.25 | -$0.32 | -$0.37 - -$0.14 | +21.88% | Beat | N/A | 4 | N/A | Aug 10, 2020 | $23.09M |
| Mar 31, 2020 | -$0.22 | -$0.20 | -$0.35 - -$0.14 | -10.00% | Miss | N/A | 4 | N/A | May 13, 2020 | $26.17M |
| Dec 31, 2019 | -$1.11 | -$0.26 | -$0.26 - -$0.26 | -326.92% | Miss | N/A | 1 | N/A | Mar 16, 2020 | $25.83M |
| Sep 30, 2019 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Oct 30, 2019 | $19.96M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.92, after -$2.61 the year before. It was -$1.12 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.92 | N/A |
| Dec 31, 2024 | -$2.61 | N/A |
| Dec 31, 2023 | -$1.94 | N/A |
| Dec 31, 2022 | -$1.32 | N/A |
| Dec 31, 2021 | -$1.40 | N/A |
| Dec 31, 2020 | -$0.87 | N/A |
| Dec 31, 2019 | -$1.12 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,700 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,696 | 12 | |
| 2026Q2 | Jun 30, 2026 | 4,079 | 11 | |
| 2026Q1 | Mar 31, 2026 | 5,602 | 13 | |
| 2025Q4 | Dec 31, 2025 | 7,231 | 11 | |
| 2025Q3 | Sep 30, 2025 | 5,937 | 13 | |
| 2025Q2 | Jun 30, 2025 | 4,919 | 12 | |
| 2025Q1 | Mar 31, 2025 | 5,043 | 9 | |
| 2024Q4 | Dec 31, 2024 | 7,470 | 15 |
2026Q3 Earnings Call
Opening remarks
Jaren Madden Chief Corporate Affairs Officer and Head of Investor Relations Thank you, and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our third quarter 2026 financial results. Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at schrodinger.com. During today's call, management will make statements that are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our outlook for the full year 2026, our plans to accelerate the growth of our software business and advance our therapeutics portfolio, the capability and potential advantages of Bunsen, our Agentic AI co-scientist, the clinical potential and properties of our compounds and those of our collaborators, the use of our cash resources, as well as our future expenses. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially due to a number of important factors, including the considerations described in the Risk Factors section and elsewhere in the filings we make with the SEC, including our Form 10-Q for the quarter ended September 30, 2026. These forward-looking statements represent our views only as of today, and we caution you that, except as required by law, we may not update them in the future, whether as a result of new information, future events or otherwise. Also included in today's call are certain non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and should be considered only in addition to and not as a substitute for or superior to GAAP measures. Please refer to the tables at the end of our press release, which is available on our website, for reconciliations of these non-GAAP measures to the most directly comparable GAAP measures. This afternoon, Ramy Farid, our CEO, will review our recent progress. Then Richie Jain, Chief Financial Officer, will discuss our financial results and 2026 guidance. Karen Akinsanya, President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships, will provide an update on our therapeutics portfolio. Pat Lorton, our Chief Technology and Chief Operating Officer, will join us for the Q&A. And with that, I will turn the call over to Ramy.
Ramy Farid CEO Thanks, Jaren, and thank you, everyone, for joining us today. Our third quarter results reflect sustained commercial momentum and strong progress toward the long-range goals we outlined earlier this year. ACV grew 17%, or 24% excluding contribution ACV.
Frequently Asked Questions About SDGR
When is Schrodinger's next earnings date?
Schrodinger's next earnings report is expected for Feb 23, 2027.
Did SDGR beat earnings estimates last quarter?
Yes. Schrodinger reported EPS of -$0.50 for the quarter ended Sep 30, 2026, above the -$0.66 estimate, a 24.24% surprise.
What EPS do analysts expect from SDGR next quarter?
The consensus EPS estimate for Schrodinger for the quarter ending Dec 31, 2026 is -$0.26 from 8 analysts, with estimates from -$0.50 to -$0.05.
How often does SDGR beat earnings estimates?
Schrodinger beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +29.08%.
SDGR pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts